QSS
ALLO icon

Quantitative Systematic Strategies’s Allogene Therapeutics ALLO Stock Holding History

Quantitative Systematic Strategies’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-6,667
Closed -$235K – 459
2021
Q1 		$235K Buy
+6,667
New +$225K 0.04% 526

Other funds holding ALLO

TGHSA
TPG Group Holdings (SBS) Advisors Fort Worth, Texas $10.1B AUM 22.58% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Quantitative Systematic Strategies's ALLO Position: Q2 2021 in Review

Quantitative Systematic Strategies sold out of Allogene Therapeutics (ALLO) in Q2 2021, closing a stake of 6,667 shares — an estimated $235K sold.

Quantitative Systematic Strategies first reported a position in ALLO in Q1 2021 and held it in 1 quarter. The position peaked at $235K in Q1 2021. 182 funds tracked by Wall St. Rank hold ALLO as of Q2 2021.

  • Quantitative Systematic Strategies reported no remaining Allogene Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Quantitative Systematic Strategies sold 6,667 Allogene Therapeutics shares in Q2 2021, an estimated $235K.
  • Quantitative Systematic Strategies first reported a position in Allogene Therapeutics in Q1 2021 and held it in 1 quarter.
  • Quantitative Systematic Strategies's Allogene Therapeutics position peaked at $235K in Q1 2021.
  • 182 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q2 2021.

Based on Quantitative Systematic Strategies's 13F filing for Q2 2021, filed 5 Aug 2021.